Browse our 650+ Publications​

Latest Publications

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.

Younes A, et al.
Blood Advances
April 2023
Authors and Affiliates
Anas Younes,1 John M. Burke,2 Bruce D. Cheson,3 Catherine S. Diefenbach,4 Silvia Ferrari,5 Uwe H. Hahn,6 Eliza A. Hawkes,7 Cyrus Khan,8 Izidore S. Lossos,9 Gerardo Musuraca,10 Monica Tani,11 Umberto Vitolo,12 Sam Yuen,13 Aparna Raval,14 Mahesh Shivhare,15 Tina G. Nielsen,16 Gila Sellam,16 Jeff P. Sharman,17 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; 2Rocky Mountain Cancer Centers & US Oncology, Aurora, CO, USA; 3Georgetown University Hospital, Washington, DC, USA*; 4 Clinical Lymphoma program, Perlmutter Cancer Center at NYU Langone Health, New York City, NY, USA; 5Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; 6Department of Haematology, Royal Adelaide and Queen Elizabeth Hospital, Adelaide, SA, Australia; 7Department of Haematology,Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia; 8Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA; 9Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA; 10Hematology unit, IRCCS, Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy; 11Division of Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy; 12Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy; 13Department of Haematology, Calvary Mater, Newcastle, NSW, Australia; 14Oncology Biomarker Development,Genentech, Inc, South San Francisco, CA, USA**; 15Data and statistical Science, Roche Products Ltd, Welwyn Garden City, United Kingdom; 16Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; 17US Oncology Research, Willamette Valley Cancer Institute / US Oncology Research, Eugene, OR, USA

Interpretable artificial intelligence model for accurate identification of medical conditions using immune repertoire

Zhao Y, et al.
April 2023
Authors and Affiliates
Yu Zhao 1, Bing He 1, Zhimeng Xu 1, Yidan Zhang 1,2, Xuan Zhao 1, Zhi-An Huang 1,3, Fan Yang 1, Liang Wang 1, Lei Duan 2, Jiangning Song 1,4, Jianhua Yao 1; 1 AI Lab, Tencent, Shenzhen, China. 2 School of Computer Science, Sichuan University, Chengdu, China. 3 Center for Computer Science and Information Technology, City University of Hong Kong Dongguan Research Institute, Dongguan, China. 4 Monash Biomedicine Discovery Institute and Monash Data Futures Institute, Monash University, Melbourne, VIC 3800, Australia.

Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer

Yoshida-Court K, et al.
April 2023
Authors and Affiliates
Kyoko Yoshida-Court 1, Tatiana V Karpinets 2, Aparna Mitra 1, Travis N Solley 1, Stephanie Dorta-Estremera 3, Travis T Sims 4, Andrea Y Delgado Medrano 1, Molly B El Alam 1, Mustapha Ahmed-Kaddar 1, Erica J Lynn 1, K Jagannadha Sastry 5, Jianhua Zhang 2, Andrew Futreal 2, Alpa Nick 6,7, Karen Lu 4, Lauren E Colbert 1, Ann H Klopp 1; 1 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. 2 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. 3 Comprehensive Cancer Center, Cancer Biology, Department of Microbiology and Zoology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico. 4 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. 5 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. 6 Saint Thomas Health/Ascension, Nashville, TN, United States of America. 7 Tennessee Oncology, Nashville, Tennessee, United States of America.

Clonally expanded HIV-1 proviruses with 5′-leader defects can give rise to nonsuppressible residual viremia

White JA, et al.
April 2023
Authors and Affiliates
Jennifer A White 1, Fengting Wu 1, Saif Yasin 2, Milica Moskovljevic 1, Joseph Varriale 1, Filippo Dragoni 1, Angelica Camilo-Contreras 1, Jiayi Duan 1, Mei Y Zheng 2, Ndeh F Tadzong 2, Heer B Patel 2, Jeanelle Mae C Quiambao 2, Kyle Rhodehouse 1, Hao Zhang 3, Jun Lai 1, Subul A Beg 1, Michael Delannoy 4, Christin Kilcrease 1, Christopher J Hoffmann 1, Sébastien Poulin 5, Frédéric Chano 5, Cécile Tremblay 6,7, Jerald Cherian 1, Patricia Barditch-Crovo 1, Natasha Chida 1, Richard D Moore 1, Michael F Summers 2,8, Robert F Siliciano 1,8, Janet D Siliciano 1, Francesco R Simonetti 1; 1 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2 Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, Baltimore, Maryland, USA. 3 Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 4 Institute for Basic Biomedical Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5 Clinique L'Agora, Montreal, Canada. 6 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Canada. 7 Département de Microbiologie, Immunologie et Infectiologie, Université de Montréal, Montreal, Canada. 8 Howard Hughes Medical Institute, Baltimore, Maryland, USA.

Thymic atrophy creates holes in Treg-mediated immuno-regulation via impairment of an antigen-specific clone

Thomas R, et al.
April 2023
Authors and Affiliates
Rachel Thomas 1, Jiyoung Oh 2, Weikan Wang 1, Dong-Ming Su 3; 1 Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA. 2 Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3 Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA.

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Sinha M, et al.
April 2023
Authors and Affiliates
Meenal Sinha 1, Courtney Betts 2, Li Zhang 1,3, Madeline J Griffith 1, Isabelle Solman 4, Brandon Chen 1, Eric Liu 1, Whitney Tamaki 1, Jacob Stultz 1, Jaqueline Marquez 1, Shamilene Sivagnanam 2, Alexander Cheung 1, Denise Pener 5, Anne Fahlman 5, Erin Taber 5, Kimberly Lerner 5, Matthew Crocker 5, Kendra Todd 5, Brindha Rajagopalan 5, Clarisha Ware 1, Mark Bridge 1, Johnson Vo 5, Hannah Dragomanovich 1, Julie Sudduth-Klinger 1, Gina Vaccaro 6, Charles D Lopez 2,5, Margaret Tempero 1, Lisa M Coussens # 2, Lawrence Fong # 7,8; 1 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA. 2 Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA. 3 Department of Biostatistics, University of California, San Francisco, California, USA. 4 AbbVie, Irvine, California, USA. 5 Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA. 6 Medical Oncology, Providence Portland Medical Center, Portland, Oregon, USA. 7 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA lawrence.fong@ucsf.edu. 8 Parker Institute for Cancer Immunotherapy, San Francisco, California, USA. #Contributed equally.

Perturbations of the T-cell immune repertoire in kidney transplant rejection

Sigdel TK, et al.
April 2023
Authors and Affiliates
Tara K Sigdel 1, Paul A Fields 2, Juliane Liberto 1, Izabella Damm 1, Maggie Kerwin 1, Jill Hood 2, Parhom Towfighi 1, Marina Sirota 1, Harlan S Robins 2, Minnie M Sarwal 1; 1 Department of Surgery, Division of Multi Organ Transplantation, University of California, San Francisco, San Francisco, CA, United States. 2 Adaptive Biotechnologies, Seattle, WA, United States.

BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells

Romine KA, et al.
April 2023
Authors and Affiliates
Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid-derived suppressor cells, suppressive regulatory T cells and dysfunctional T cells. Similarly, we have identified the same immune-related features, including exhausted CD8+ T cells (TEx) in a mouse model of AML. Here we show that inhibitors that target bromodomain and extra-terminal domain (BET) proteins affect tumor-intrinsic factors but also rescue T cell exhaustion and ICB resistance. Ex vivo treatment of cells from AML mice and AML patients with BET inhibitors (BETi) reversed CD8+ T cell exhaustion by restoring proliferative capacity and expansion of the more functional precursor-exhausted T cells. This reversal was enhanced by combined BETi and anti-PD1 treatment. BETi synergized with anti-PD1 in vivo, resulting in the reduction of circulating leukemia cells, enrichment of CD8+ T cells in the bone marrow, and increase in expression of Tcf7, Slamf6, and Cxcr5 in CD8+ T cells. Finally, we profiled the epigenomes of in vivo JQ1-treated AML-derived CD8+ T cells by single-cell ATAC-seq and found that JQ1 increases Tcf7 accessibility specifically in Tex cells, suggesting that BETi likely acts mechanistically by relieving repression of progenitor programs in Tex CD8+ T cells and maintaining a pool of anti-PD1 responsive CD8+ T cells.

Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

Palomero J, et al.
April 2023
Authors and Affiliates
Jara Palomero 1, Carla Panisello 1, Maria Lozano-Rabella 1, Ricky Tirtakasuma 1, Judit Díaz-Gómez 1, Daniela Grases 1, Helena Pasamar 1, Laura Arregui 2, Eduard Dorca Duch 3, Esther Guerra Fernández 3, Ana Vivancos 4, Carlos E de Andrea 5,6, Ignacio Melero 6,7,8, Jordi Ponce 9, August Vidal 3,6, Josep Maria Piulats 10, Xavier Matias-Guiu 3,6,11, Alena Gros 12; 1 Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. 2 HUB-ICO-IDIBELL Biobank, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain. 3 Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain. 4 Cancer Genomics, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. 5 Pathology, Clinica Universidad de Navarra, Pamplona, Spain. 6 Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain. 7 Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. 8 Navarra Institute for Health Research IDISNA, Pamplona, Spain. 9 Department of Gynaecology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain. 10 Medical Oncology, Catalan Institute of Oncology (ICO), IDIBELL-OncoBell, L'Hospitalet de Llobregat, Spain. 11 Pathology, Arnau de Vilanova University Hospital, University of LLeida, IRBLLEIDA, Lleida, Spain. 12 Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain agros@vhio.net.
Previous Next